Smartleaf Asset Management
CMPX icon

Smartleaf Asset Management’s Compass Therapeutics CMPX Stock Holding History

Smartleaf Asset Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-69
Closed -$149 – 3664
2026
Q2 		$149 Hold
69
– – ﹤0.01% 3332
2026
Q1 		$352 Hold
69
– – ﹤0.01% 3272
2025
Q4 		$371 Buy
+69
New +$319 ﹤0.01% 3296

Other funds holding CMPX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Royce & Associates
Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Smartleaf Asset Management's CMPX Position: Q3 2026 in Review

Smartleaf Asset Management sold out of Compass Therapeutics (CMPX) in Q3 2026, closing a stake of 69 shares — an estimated $149 sold.

Smartleaf Asset Management first reported a position in CMPX in Q4 2025 and held it in 3 quarters. The position peaked at $371 in Q4 2025. 68 funds tracked by Wall St. Rank hold CMPX as of Q3 2026.

  • Smartleaf Asset Management reported no remaining Compass Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Smartleaf Asset Management sold 69 Compass Therapeutics shares in Q3 2026, an estimated $149.
  • Smartleaf Asset Management first reported a position in Compass Therapeutics in Q4 2025 and held it in 3 quarters.
  • Smartleaf Asset Management's Compass Therapeutics position peaked at $371 in Q4 2025.
  • 68 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2026.

Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.